Phathom Pharmaceuticals, Inc. (NasdaqGS: PHAT)
Health Care · Pharmaceuticals · US
$7.25
+4.77% today · -42.1% 1Y
Phathom Pharmaceuticals, Inc. (NasdaqGS: PHAT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $575.87M and employs 371 people.
Over the last twelve months the share price has lost 42.1%, trading between 6.52 and 18.31.
Tweenvest scores Phathom Pharmaceuticals, Inc. across four factors: quality 22/100, value 78/100. Its strongest factor is value.
PHAT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $575.87M
- Revenue (TTM)
- $239.66M
- P/E
- —
- EPS
- -1.27
- Dividend yield
- —
- Beta (5Y)
- 0.50
- 52-week high
- $18.31
- 52-week low
- $6.52
- Avg volume (3M)
- —
- Shares outstanding
- 79.43M
- Employees
- 371
- Next earnings
- —
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
- ISIN
- US71722W1071
- Founded
- 2018
- Listed since
- Oct 25, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Xiao Fang Pharmaceutical Co.,Ltd.SHSE: 603207 | $586.98M | CN¥24.47 | +0.04% |
| Huaren Pharmaceutical Co., Ltd.SZSE: 300110 | $584.21M | CN¥3.31 | +4.42% |
| Qianjiang Yongan Pharmaceutical Co., Ltd.SZSE: 002365 | $581.48M | CN¥13.47 | -0.07% |
| Zhejiang Yatai Pharmaceutical Co., Ltd.SZSE: 002370 | $580.00M | CN¥5.21 | +0.97% |
| CorMedix Inc.NasdaqGM: CRMD | $575.23M | $7.38 | +0.82% |
| Zhejiang Starry Pharmaceutical Co.,Ltd.SHSE: 603520 | $570.75M | CN¥8.72 | -0.34% |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTDSZSE: 300534 | $567.01M | CN¥12.52 | -0.48% |
| Aclaris Therapeutics, Inc.NasdaqGS: ACRS | $563.77M | $3.83 | +1.06% |
Figures last refreshed Oct 11, 2026.